Isomorphic Labs Raises $5 Billion to Solve All Disease with AI
Demis Hassabis announced that Isomorphic Labs, the AI drug-discovery company he founded in 2021 on the back of AlphaFold, has raised $5 billion to accelerate its mission of "solving all disease." It is one of the largest funding rounds ever in AI-driven drug development, underscoring continued capital-market bets on AI-powered drug R&D.
Confirmed
- The $5 billion raise is a Series C, co-led by Greenocks and Sequoia Capital, with new investors including a16z
- Thrive, MGX, GV and others participated, with Alphabet continuing to invest heavily
- Hassabis spun the company out of DeepMind in 2021 with the mission of "solving all disease"
- The company aims to redesign drugs from first principles using AI, dramatically shortening drug-discovery timelines
- Per @TorturedPoet30, five years after founding no drug has yet entered human trials
Why it matters
- The $5 billion scale far exceeds typical biotech raises, reflecting Alphabet's and top VCs' long-term confidence in the "AI + drug discovery" space
- AlphaFold's breakthroughs in protein structure prediction underpin the company's technology, making this round a key commercialization milestone
- The "no drugs in human trials yet" point raised by @TorturedPoet30 is the main controversy: the contrast between massive capital inflows and an empty clinical pipeline will put the company's future progress under intense scrutiny
2026-11-17 ~ 2026-11-17 · 6 related posts
Primary sources
- [source] Isomorphic Labs raises $5B to accelerate AI-first drug design, says Demis Hassabis — demishassabis · 2026-11-17
- [source] Isomorphic Labs raises $5B Series C, five years in with no drug yet in human trials — TorturedPoet30 · 2026-11-17
- Isomorphic Labs raises $5B Series C co-led by Greenoaks and Sequoia — SergeiIakhnin · 2026-11-17
3 near-duplicate retellings: daniel_mac8 · heyshrutimishra · kimmonismus